• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Neuropace Inc. (Amendment)

    2/14/23 8:22:53 AM ET
    $NPCE
    Medical/Dental Instruments
    Health Care
    Get the next $NPCE alert in real time by email
    SC 13G/A 1 d443703dsc13ga.htm SC 13G/A SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    NEUROPACE, INC.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    641288105

    (CUSIP Number)

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP NO. 641288105

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Soleus Private Equity Fund I, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

      (a)  ☐        (b)  ☐

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      592,186 (1)

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      592,186 (1)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      592,186 (1)

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      2.4% (2)

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      PN

    FOOTNOTES

     

    (1)

    The shares are owned directly by Soleus Private Equity Fund I, L.P. (“Soleus PE”). Soleus Private Equity GP I, LLC (“Soleus GP”) is the sole general partner of Soleus PE. Soleus GP holds voting and dispositive power over the shares held by Soleus PE. Soleus PE GP I, LLC is the sole manager of Soleus GP. Mr. Guy Levy is the sole managing member of Soleus PE GP I, LLC. Each of Mr. Guy Levy, Soleus PE GP I, LLC and Soleus GP disclaims beneficial ownership of these securities held by Soleus PE and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or for any other purpose, except to the extent of their respective pecuniary interests therein.

    (2)

    This percentage is calculated based upon 24,903,146 shares of common stock outstanding of NeuroPace, Inc. (the “Issuer”) as of November 4, 2022, as set forth on the cover of the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022, which was filed with the Securities and Exchange Commission (the “SEC”) on November 8, 2022 (the “Form 10-Q”).


    CUSIP NO. 641288105

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Soleus Private Equity GP I, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

      (a)  ☐        (b)  ☐

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      592,186 (1)

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      592,186 (1)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      592,186 (1)

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      2.4% (2)

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO

    FOOTNOTES

     

    (1)

    The shares of common stock reported in this row are owned directly by Soleus PE. Soleus GP is the sole general partner of Soleus PE. Soleus GP holds voting and dispositive power over the shares held by Soleus PE. Soleus PE GP I, LLC is the sole manager of Soleus GP. Mr. Guy Levy is the sole managing member of Soleus PE GP I, LLC.

    (2)

    This percentage is calculated based upon 24,903,146 shares of common stock outstanding of the Issuer as of November 4, 2022, as set forth on the front cover of the Form 10-Q.


    CUSIP NO. 641288105

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Soleus PE GP I, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

      (a)  ☐        (b)  ☐

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      592,186 (1)

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      592,186 (1)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      592,186 (1)

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      2.4% (2)

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO

    FOOTNOTES

     

    (1)

    The shares of common stock reported in this row are owned directly by Soleus PE. Soleus GP is the sole general partner of Soleus PE. Soleus GP holds voting and dispositive power over the shares held by Soleus PE. Soleus PE GP I, LLC is the sole manager of Soleus GP. Mr. Guy Levy is the sole managing member of Soleus PE GP I, LLC.

    (2)

    This percentage is calculated based upon 24,903,146 shares of common stock outstanding of the Issuer as of November 4, 2022, as set forth on the front cover of the Form 10-Q.


    CUSIP NO. 641288105

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Soleus Capital Master Fund, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

      (a)  ☐        (b)  ☐

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Cayman Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      1,776,817 (1)

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      1,776,817 (1)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,776,817 (1)

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      7.1% (2)

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      FI

    FOOTNOTES

     

    (1)

    The shares of common stock reported in this row are held by Soleus Capital Master Fund, L.P. (“Master Fund”). Soleus Capital, LLC is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC. Mr. Guy Levy is the sole managing member of Soleus Capital Group, LLC. Each of Soleus Capital Group, LLC, Soleus Capital, LLC and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein.

    (2)

    This percentage is calculated based upon 24,903,146 shares of common stock outstanding of the Issuer as of November 4, 2022, as set forth on the front cover of the Form 10-Q.


    CUSIP NO. 641288105

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Soleus Capital, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

      (a)  ☐        (b)  ☐

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      1,776,817 (1)

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      1,776,817 (1)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,776,817 (1)

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      7.1% (2)

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO

    FOOTNOTES

     

    (1)

    The shares of common stock reported in this row are held by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC. Mr. Guy Levy is the sole managing member of Soleus Capital Group, LLC.

    (2)

    This percentage is calculated based upon 24,903,146 shares of common stock outstanding of the Issuer as of November 4, 2022, as set forth on the front cover of the Form 10-Q.


    CUSIP NO. 641288105

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Soleus Capital Group, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

      (a)  ☐        (b)  ☐

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      1,776,817 (1)

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      1,776,817 (1)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,776,817 (1)

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      7.1% (2)

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO

    FOOTNOTES

     

    (1)

    The shares of common stock reported in this row are held by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC.

    (2)

    This percentage is calculated based upon 24,903,146 shares of common stock outstanding of the Issuer as of November 4, 2022, as set forth on the front cover of the Form 10-Q.


    CUSIP NO. 641288105

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Guy Levy

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

      (a)  ☐        (b)  ☐

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      2,369,003 (1)

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      2,369,003 (1)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,369,003 (1)

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      9.5% (2)

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IN

    FOOTNOTES

     

    (1)

    592,186 of the shares of common stock reported in this row are held directly by Soleus PE and 1,776,817 of the shares of common stock reported in this row are held directly by Master Fund. Soleus GP is the sole general partner of Soleus PE, Soleus PE GP I, LLC is the sole manager of Soleus GP, and Mr. Guy Levy is the sole managing member of Soleus PE GP I, LLC. Soleus Capital, LLC is the sole general partner of Master Fund, Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC, and Mr. Guy Levy is the sole managing member of Soleus Capital Group, LLC. Mr. Guy Levy disclaims beneficial ownership of these securities held by Soleus PE and Master Fund, and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of his pecuniary interest therein.

    (2)

    This percentage is calculated based upon 24,903,146 shares of common stock outstanding of the Issuer as of November 4, 2022, as set forth on the front cover of the Form 10-Q.


    Item 1.

     

      (a)

    Name of Issuer

    NeuroPace, Inc.

     

      (b)

    Address of Issuer’s Principal Executive Offices

    455 N. Bernardo Avenue

    Mountain View, CA 94043

    Item 2.

     

      (a)

    Name of Person(s) Filing

    Soleus Private Equity GP I, LLC

    Soleus Private Equity Fund I, L.P.

    Soleus PE GP I, LLC

    Soleus Capital Master Fund, L.P.

    Soleus Capital, LLC

    Soleus Capital Group, LLC

    Guy Levy

     

      (b)

    Address of Principal Business Office or, if none, Residence

    Soleus Private Equity GP I, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

    Soleus Private Equity Fund I, L.P.

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

    Soleus PE GP I, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

    Soleus Capital Master Fund, L.P.

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

    Soleus Capital, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

    Soleus Capital Group, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

    Guy Levy

    c/o Soleus Capital Management, L.P

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830


      (c)

    Citizenship

    Soleus Private Equity GP I, LLC – Delaware

    Soleus Private Equity Fund I, L.P. – Delaware

    Soleus PE GP I, LLC – Delaware

    Soleus Capital Master Fund, L.P. – Cayman Islands

    Soleus Capital, LLC – Delaware

    Soleus Capital Group, LLC – Delaware

    Guy Levy – United States

     

      (d)

    Title of Class of Securities

    Common Stock

     

      (e)

    CUSIP Number

    641288105

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

             (a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
      (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
      (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. ☐78c).
      (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
      (e)    ☐    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
      (f)    ☐    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
      (g)    ☐    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
      (h)    ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
      (j)    ☐    A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).
      (k)    ☐    Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

    Item 4. Ownership.

    Reference is made to Items 5 – 11 on the preceding pages of this Schedule 13G.


    As of December 31, 2022, Master Fund and Soleus PE (collectively, the “Funds”) collectively hold an aggregate of 2,369,003 common shares (the “Shares”) of the Issuer.

    As the general partner of Soleus PE, Soleus GP may be deemed to have shared power to vote or direct the vote and to dispose or to direct the disposition of the Shares held by Soleus PE. As the sole manager of Soleus GP, Soleus PE GP I, LLC may be deemed to have shared power to vote or to direct the vote and to dispose or direct the disposition of the Shares held by Soleus PE. As the sole managing member of Soleus PE GP I, LLC, Mr. Guy Levy may be deemed to have shared power to vote or direct the vote and to dispose or to direct the disposition of the Shares held by Soleus PE.

    As the general partner of Master Fund, Soleus Capital, LLC may be deemed to have shared power to vote or direct the vote and to dispose or to direct the disposition of the Shares held by Master Fund. As the sole managing member of Soleus Capital, LLC, Soleus Capital Group, LLC may be deemed to have shared power to vote or to direct the vote and to dispose or direct the disposition of the Shares held by Master Fund. As the sole managing member of Soleus Capital Group, LLC, Mr. Guy Levy may be deemed to have shared power to vote or direct the vote and to dispose or to direct the disposition of the Shares held by Master Fund.

    Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission that Mr. Levy, Soleus PE GP I, LLC, Soleus GP, Soleus Capital, LLC or Soleus Capital Group, LLC is the beneficial owner of the Common Stock referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose, except to the extent of their respective pecuniary interest therein, and such beneficial ownership is expressly disclaimed.

    Item 5. Ownership of Five Percent or Less of a Class

    Not applicable.

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    Not applicable.

    Item 8. Identification and Classification of Members of the Group

    Not applicable.

    Item 9. Notice of Dissolution of Group

    Not applicable.


    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose, or with the effect, of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2023     Soleus Private Equity Fund I, L.P.
       

    By:

      Soleus Private Equity GP I, LLC, its General Partner
       

    By:

      Soleus PE GP I, LLC, its Manager
        By:   /s/ Guy Levy
       

    Name:

      Guy Levy
       

    Title:

      Managing Member
    Date: February 14, 2023     Soleus Private Equity GP I, LLC
       

    By:

      Soleus PE GP I, LLC, its Manager
        By:   /s/ Guy Levy
       

    Name:

      Guy Levy
       

    Title:

      Managing Member
    Date: February 14, 2023     Soleus PE GP I, LLC
        By:   /s/ Guy Levy
       

    Name:

      Guy Levy
       

    Title:

      Managing Member
    Date: February 14, 2023     Soleus Capital Master Fund, L.P.
       

    By:

      Soleus Capital, LLC, its General Partner
       

    By:

      Soleus Capital Group, LLC, its Managing Manager
        By:   /s/ Guy Levy
       

    Name:

      Guy Levy
       

    Title:

      Managing Member


    Date: February 14, 2023     Soleus Capital, LLC
       

    By:

      Soleus Capital Group, LLC, its Managing Manager
        By:   /s/ Guy Levy
       

    Name:

      Guy Levy
       

    Title:

      Managing Member
    Date: February 14, 2023     Soleus Capital Group, LLC
        By:   /s/ Guy Levy
       

    Name:

      Guy Levy
       

    Title:

      Managing Member
    Date: February 14, 2023     /s/ Guy Levy
       

    Name:

      Guy Levy

    Footnotes:

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

    Get the next $NPCE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NPCE

    DatePrice TargetRatingAnalyst
    5/28/2025$18.00Buy
    H.C. Wainwright
    1/21/2025$17.00Buy
    UBS
    3/14/2024$16.00 → $20.00Equal Weight → Overweight
    Wells Fargo
    1/30/2024$22.00Outperform
    Leerink Partners
    11/10/2023$11.00Overweight
    Cantor Fitzgerald
    8/24/2023$5.00 → $6.00Underweight → Equal-Weight
    Morgan Stanley
    2/22/2023$10.00Buy
    Lake Street
    4/6/2022$13.00Outperform
    Wolfe Research
    More analyst ratings

    $NPCE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NeuroPace to Participate in Upcoming Healthcare Conferences

    NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in two healthcare conferences in September. NeuroPace management will host one-on-one meetings with investors at the Wells Fargo 2025 Healthcare Conference, on Wednesday, September 3 in Boston, MA. NeuroPace management will participate in a fireside chat discussion at the Cantor Global Healthcare Conference on Thursday, September 4 at 9:45am ET, and host one-on-one meetings with investors during the conference. The fireside chat will be accessible via a live webcast here and a replay will be available on the

    8/28/25 8:00:00 AM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    NeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

    -- Reported record quarterly revenue of $23.5 million in Q2 2025-- -- Increased full-year 2025 revenue guidance to between $94 million and $98 million and gross margin guidance to between 75% and 76%-- -- Remain on track to submit NAUTILUS data to FDA for potential IGE indication expansion in the second half of 2025— --CMS maintains current MS-DRG assignment for RNS System® procedures-- MOUNTAIN VIEW, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update. Second Quarter

    8/12/25 4:05:00 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases

    MOUNTAIN VIEW, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical technology company focused on transforming the lives of people living with epilepsy, today issued the following statement in response to the Centers for Medicare & Medicaid Services (CMS) electing not to finalize its proposed reassignment of epilepsy with neurostimulator cases in the FY 2026 Inpatient Prospective Payment System (IPPS) rule. "We appreciate CMS' openness to public comment on the proposed rule and its reconsideration of the original proposal to reassign RNS cases to MS-DRG 020-022. We commend CMS' decision to maintain the current MS-DRG assignment for RNS® System procedures un

    8/1/25 7:30:00 AM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    $NPCE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on NeuroPace with a new price target

    H.C. Wainwright initiated coverage of NeuroPace with a rating of Buy and set a new price target of $18.00

    5/28/25 9:08:28 AM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    UBS initiated coverage on NeuroPace with a new price target

    UBS initiated coverage of NeuroPace with a rating of Buy and set a new price target of $17.00

    1/21/25 8:23:18 AM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    NeuroPace upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded NeuroPace from Equal Weight to Overweight and set a new price target of $20.00 from $16.00 previously

    3/14/24 8:11:10 AM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    $NPCE
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Neuropace Inc.

    SCHEDULE 13G/A - NeuroPace Inc (0001528287) (Subject)

    8/14/25 6:03:09 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Neuropace Inc.

    10-Q - NeuroPace Inc (0001528287) (Filer)

    8/12/25 5:16:33 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    Neuropace Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NeuroPace Inc (0001528287) (Filer)

    8/12/25 4:08:15 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    $NPCE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF MEDICAL OFFICER Morrell Martha covered exercise/tax liability with 1,337 shares, decreasing direct ownership by 2% to 83,480 units (SEC Form 4)

    4 - NeuroPace Inc (0001528287) (Issuer)

    9/4/25 8:24:01 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    CHIEF MEDICAL OFFICER Morrell Martha covered exercise/tax liability with 357 shares, decreasing direct ownership by 0.42% to 84,817 units (SEC Form 4)

    4 - NeuroPace Inc (0001528287) (Issuer)

    8/28/25 4:15:08 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    CHIEF EXECUTIVE OFFICER Becker Joel covered exercise/tax liability with 1,126 shares, decreasing direct ownership by 1% to 104,212 units (SEC Form 4)

    4 - NeuroPace Inc (0001528287) (Issuer)

    8/28/25 4:15:12 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    $NPCE
    Leadership Updates

    Live Leadership Updates

    View All

    NeuroPace Announces Strategic CFO Transition

    Appoints Patrick F. Williams as Chief Financial Officer Williams Brings a Track Record of Leading Medical Device Public Companies as CFO Rebecca Kuhn Departing Company and Will Remain in Advisory Role MOUNTAIN VIEW, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointment of Mr. Patrick F. Williams as Chief Financial Officer, effective June 20, 2025. Ms. Rebecca Kuhn has entered into an agreement with the Company to depart from her CFO role and serve in an advisory role to the Company for a twelve-month period. "NeuroPace is pleased to have a finan

    6/24/25 4:05:00 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    NeuroPace Continues to Strengthen Management Team

    MOUNTAIN VIEW, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointment of Amy Treadwell as its new Vice President of Human Resources, effective immediately. "We are excited to have Amy join the team and help us continue to build an engaged, high-performing culture that supports our growth," said Joel Becker, Chief Executive Officer of NeuroPace. "We are at an important point in our growth with a number of significant commercial, operating, and technological opportunities in front of us. We believe Amy's appointment, along with the recent appointments

    10/16/24 4:05:00 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    NeuroPace Strengthens Management Team with Two Key Appointments

    Appointed former key developer of RNS System as new Vice President of Research and Development Appointed former head of commercial marketing for Boston Scientific's DBS franchise as the new Vice President of Marketing MOUNTAIN VIEW, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointments of Brett Wingeier as the new Vice President of Research and Development and Katie Keller as the new Vice President of Marketing, effective immediately. "We are excited to welcome Katie and Brett to our team. Katie brings an understanding of the neurostimulation ma

    9/4/24 4:05:00 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    $NPCE
    Financials

    Live finance-specific insights

    View All

    NeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

    -- Reported record quarterly revenue of $23.5 million in Q2 2025-- -- Increased full-year 2025 revenue guidance to between $94 million and $98 million and gross margin guidance to between 75% and 76%-- -- Remain on track to submit NAUTILUS data to FDA for potential IGE indication expansion in the second half of 2025— --CMS maintains current MS-DRG assignment for RNS System® procedures-- MOUNTAIN VIEW, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update. Second Quarter

    8/12/25 4:05:00 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    NeuroPace to Report Second Quarter 2025 Financial Results on August 12, 2025

    MOUNTAIN VIEW, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the second quarter of 2025 after market close on Tuesday, August 12, 2025. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). Investors interested in listening to the conference call may do so by accessing a live webcast of the event at https://viavid.webcasts.com/starthere.jsp?ei=1724652&tp_key=858d589533. Individuals interested in participating in the call via telephone may acces

    7/29/25 4:05:00 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study

    -- NeuroPace has completed the primary endpoint analysis of the one-year data from the first and only clinical study to evaluate neuromodulation therapy for idiopathic generalized epilepsy -- Study met the 12-week post-implant primary safety endpoint, demonstrating excellent safety outcomes and confirming favorable safety profile of the RNS® System -- Primary effectiveness endpoint did not reach statistical significance in overall study population but showed a statistically significant response in a subset, which represents the majority of participants -- Preliminary data illustrates the overall value of the RNS System to individualize patient treatment over time, showing mor

    5/27/25 8:00:00 AM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    $NPCE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Neuropace Inc.

    SC 13G/A - NeuroPace Inc (0001528287) (Subject)

    11/14/24 6:30:12 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neuropace Inc.

    SC 13G/A - NeuroPace Inc (0001528287) (Subject)

    11/14/24 3:36:16 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neuropace Inc.

    SC 13G/A - NeuroPace Inc (0001528287) (Subject)

    10/3/24 4:46:48 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care